Details for Patent: 6,057,305

Summary for Patent: 6,057,305

Title:	Antiretroviral enantiomeric nucleotide analogs
Abstract:	Resolved enantiomers of the formula wherein B is a purine or pyrimidine base or aza and/or deaza analogs thereof are useful in antiviral pharmaceutical compositions to treat retroviral infections.
Inventor(s):	Antonin Holy, Hana Dvorakova, Erik Desire Alice DeClercq, Jan Marie Rene Balzarini
Assignee:	Stichting Rega VZW , Institute of Organic Chemistry and Biochemistry CAS
Application Number:	US07/925,610
Patent Claim Types: see list of patent claims	Use;

US Patent 6,057,305 Patent Estate Deep-Dive: Method-of-Treatment Claims, Scope, Enantiomer Requirements, and US Landscape for HIV and Hepatitis B Antiviral Uses

What does US Patent 6,057,305 claim, and what is the key scope trigger in the independent claim?

Executive summary: US 6,057,305 is a US method-of-use patent directed to achieving antiviral effect in a mammal with compounds of a defined chemical formula, with a critical stereochemical limitation: the claimed antiviral compound is the R isomer substantially free of its enantiomer. The independent claim also narrows the purine substitution pattern at the 6 position and then caps the formula to specific substituent classes. Claim 2 further narrows to a single compound: 9-(R)-(2-phosphonomethoxypropyl)adenine (commonly associated with adefovir-type chemistry).

Claim 1 elements mapped to enforceable scope

Claim 1 is a classic “use” claim with structural and stereochemical constraints:

1. Intended disease target / therapeutic goal

   • “A method of achieving a human immunodeficiency virus or hepatitis B virus antiviral effect in a mammal in need of such treatment.”

2. Administration requirement

   • “Administering… an antivirally effective amount” of a compound.

3. Compound formula constraint

   • “A compound of the formula IA” and “including physiologically acceptable salts.”

4. Stereochemical trigger

   • “Wherein said compound of Formula IA is the R isomer substantially free of its enantiomer.”

5. Purine substitution restriction at the 6-position

   • “B is a purine moiety substituted at the 6 position by amino, alkylamino, dialkylamino, or aralkylamino.”

6. R substitution restriction

   • “And wherein R is H” (as stated in the claim text you provided).

7. Substituent size rules

   • “Alkyl is straight or branched chain C1-C6.”
   • “Aryl is a C6-C10 aromatic group.”
   • “Aralkyl is a C1-C6 straight or branched chain alkyl-C6-C10 aromatic group.”

Practical implication: the claim is enforceable against any US-labeled method of use that administers an R-enantiomer substantially free of the S-enantiomer of the defined formula IA to achieve antiviral activity for HIV or HBV, regardless of how the sponsor characterizes mechanism, as long as the administered compound fits the formula and is formulated/controlled to satisfy the stereochemical limitation.

Claim 2 is a single-compound lock-in

Claim 2 states:

• “The method of claim 1 wherein the antiviral compound is 9-(R)-(2-phosphonomethoxypropyl)adenine.”

Practical implication: Claim 2 narrows to one compound (and its salts if covered as “compound… including physiologically acceptable salts” is read through). That makes Claim 2 the most litigation-relevant, because it reduces chemical ambiguity and focuses disputes on enantiomeric purity and whether the administrated material is “R… substantially free” of the enantiomer.

What patents protect the same chemical scaffold as US 6,057,305 in the US, and how do method claims compare with composition claims?

Executive summary: For a method-of-use patent anchored to a stereochemically defined chemical (R-enantiomer) and purine substitution, the US enforcement map usually splits into three layers: (i) chemical composition and intermediate patents for making the R isomer, (ii) formulation patents for delivering the drug to patients, and (iii) method-of-use patents like 6,057,305 that claim therapeutic administration. In US practice, the strongest overlap comes from substance/compound claims and enantiomerically pure claims, because they attack both the active ingredient and any method-of-use attempts around the same stereochemistry.

How scope typically clusters around 9-(R)-(2-phosphonomethoxypropyl)adenine

Your claim 2 points directly at adefovir-adjacent chemistry. Patent landscapes for such agents frequently include:

• enantiomer preparation and process patents (making R substantially free of S),
• crystal form / polymorph patents (if any),
• salt form patents (physiologically acceptable salts),
• pharmaceutical composition and dose/form patents (tablets, tablets with coatings, excipient packages).

The method claim 1 adds an additional enforceable layer: even if a generic makes the compound, a label or off-label administration strategy can still raise inducement or direct infringement risk if the method of use is consistent with achieving HIV/HBV antiviral effect using the R enantiomer substantially free of its enantiomer.

Method-of-use vs. composition claim leverage

• Method-of-use claims like claim 1 and claim 2 generally require proving that a physician (or the sponsor’s label/marketing) induced administration for the claimed antiviral purpose, or that a regulated product label includes the infringing use.
• Composition claims typically shift the battle earlier in litigation and are often easier to establish with chemical identity and enantiomeric purity testing.

Enantiomer requirement is central. Many design-around attempts fail because they do not satisfy the “substantially free” threshold, which can be litigated via stereochemical purity specifications.

When does US 6,057,305 expire, and how does expiration interact with exclusivity timelines (NCE, biologics, Hatch-Waxman)?

Executive summary: US patent term and any regulatory exclusivity drive the timing risk for generics and biosimilar-style competition (though biosimilars are not usually the model for classic small-molecule HIV/HBV drugs). The claim text you provided does not include filing dates, issue date, or any priority data; without that, an exact expiration date cannot be produced from the claim alone.

What can be stated from the issue number alone

• The patent is US 6,057,305.
• Issue date, expiration computation (including PTA adjustments), and priority-based term can’t be computed accurately from claim text alone.

Exclusivity interaction framework for a method-of-use drug

Even without exact dates, the litigation and entry pattern typically looks like:

• Patent expiration or loss of enforceability determines the earliest date for a non-infringing label strategy.
• If a method-of-use patent is listed in the Orange Book for the reference listed drug (RLD), a Paragraph IV notice can trigger litigation automatic stay.

But because Orange Book listing status and filing/issue dates are not provided, no exact “when” can be responsibly stated from the inputs given.

What “enantiomer substantially free” language does to generic design-around risk?

Executive summary: The stereochemical limitation (“R isomer substantially free of its enantiomer”) is the main bottleneck for competitors. It can convert what looks like a structural claim into a specification-controlled claim, where infringement hinges on measurable enantiomeric purity.

How to interpret “substantially free” in litigation terms

For enforcement:

• The patentee will typically argue infringement if the administered compound’s enantiomeric excess and impurity profile show it is R-major and S-minor under the “substantially free” threshold.
• The defendant typically responds that “substantially” is not a bright line and that test method variance affects the measured content.

For business risk management:

• If a product uses racemic material or an S-rich or R/S mixture, it is less likely to fall within claim 1 and 2.
• If a generic sells a purified R enantiomer to match pharmacology, the stereochemical limitation can increase infringement risk, especially if the label supports HIV/HBV antiviral effect “in a mammal.”

Design-around playbook implied by the claim

• Use a compound outside Formula IA scope (different B substitution pattern at the 6-position; different R group).
• Use the S enantiomer (or racemate) instead of R substantially free of S.
• Avoid the 6-position substitution classes (amino, alkylamino, dialkylamino, aralkylamino).
• Use a different purine core or substitution location.

However: claim 2’s compound identity pins the pathway: if a product is chemically the same as 9-(R)-(2-phosphonomethoxypropyl)adenine and R-purity matches “substantially free,” the design-around options narrow sharply.

How broad is the Formula IA claim 1, and what substitution space is covered at the 6-position of the purine?

Executive summary: Claim 1 covers a defined family around a purine scaffold with a constrained substitution pattern at the 6-position and with tight control over R isomer and R being H. The breadth is controlled more by the formula structure than by dosage or administration mode.

Substitution breadth at the 6-position (B moiety)

The claim includes:

• amino
• alkylamino where alkyl is C1-C6 straight or branched
• dialkylamino where each alkyl is C1-C6 (based on typical reading)
• aralkylamino where aralkyl is C1-C6 alkyl attached to C6-C10 aromatic

Net effect: a competitor must not merely tweak one group; it must fall outside these enumerated classes or outside the formula constraints. Even within these classes, stereochemistry remains locked to R isomer substantially free of the enantiomer.

What “R is H” does to scope

“Wherein R is H” eliminates any analog where the substituent corresponding to R is not hydrogen. That blocks a common medicinal chemistry pivot: adding substituents on the scaffold where R controls a position (as represented in the formula IA definition).

What FDA Orange Book status and Paragraph IV risks exist for US 6,057,305?

Executive summary: Orange Book risk assessment requires: (i) identification of the reference listed drug (RLD), (ii) whether US 6,057,305 is listed for that RLD, and (iii) which patents and method-of-use entries are active. The claim text provided does not include Orange Book identifiers, RLD name, NDA/BLA numbers, or listing status.

Because those inputs are not present, an Orange Book status call cannot be produced from the provided information.

How strong is the patent estate for this class: what claims typically attack generics beyond US 6,057,305?

Executive summary: A method claim with a stereochemical limitation typically sits among a family of related US filings. Even if US 6,057,305 is the asserted method patent, generic entry risk is usually driven by:

• compound/enantiomer patents covering R-isomer synthesis and composition,
• process patents for preparing the enantiomerically pure material,
• formulation or salt patents that keep the administered product within claim boundaries.

Litigation leverage points tied to this claim’s wording

1. Enantiomeric purity testing

   • A generic that sells R-enantiomer to match pharmacology may still need to show how much S is present and how that compares to “substantially free.”

2. Label-based method of use

   • If the label or promotional materials claim HIV/HBV antiviral effect consistent with the claim’s purpose, the method claim can be asserted even when chemical structure is identical.

3. Salt coverage

   • Claim 1 includes “physiologically acceptable salts,” so substituting a salt form is not a clean design-around unless it takes the product outside the formula limitations or introduces a stereochemical shift.

What prior art constraints likely shape the claim’s novelty, and where might it be vulnerable?

Executive summary: Without the patent specification, priority chain, and prosecution history, a novelty or obviousness attack can’t be mapped precisely. The claim’s emphasis on R-enantiomer purity and purine substitution strongly suggests the novelty hook is stereoselectivity and a particular substitution pattern. That does not eliminate vulnerability; it frames where the defense and invalidity arguments would concentrate.

Likely vulnerability focus areas in disputes (derived from claim text)

• Whether R vs S separation or R-enantiomer isolation was known and whether “substantially free” is taught.
• Whether the purine 6-position substituted classes are disclosed in prior art in a way that renders the claimed family obvious.
• Whether the specific compound of claim 2 is already disclosed as an antiviral with R stereochemistry and whether it was within routine optimization.

But any actual invalidity analysis requires the patent’s bibliographic data and the disclosed formula identity in the specification.

Key Takeaways

• US 6,057,305 claim 1 is a stereochemically limited method-of-use: it covers administering an R isomer substantially free of its enantiomer of Formula IA to achieve HIV or HBV antiviral effect.
• Claim 2 narrows to 9-(R)-(2-phosphonomethoxypropyl)adenine, making enantiomeric purity and label-based use pivotal in infringement.
• Scope breadth is constrained by formula structure (purine 6-position substitution classes, R is H) and by the R-only, S-minor purity requirement.
• Generic design-around risk is concentrated on stereochemistry: switching to racemic material or S-enantiomer, or changing the scaffold/6-position class outside the claim, are the meaningful escape routes implied by the wording.
• Timing, Orange Book listing status, and expiration dates require bibliographic and regulatory listing inputs not contained in the provided text, so they cannot be stated accurately here.

FAQs

1. Does US 6,057,305 require administering only the R enantiomer, or can mixtures still infringe?
   The claim requires the administered compound is the R isomer substantially free of its enantiomer, so mixture products hinge on measured enantiomeric purity.

2. What part of the claim most directly blocks scaffold “tweaks” by generics?
   The combination of Formula IA structural constraints plus the 6-position purine substitution classes plus the R stereochemical purity.

3. Can a competitor avoid infringement by changing from one physiologically acceptable salt to another?
   Claim 1 expressly includes “physiologically acceptable salts,” so salt changes do not, by themselves, avoid the claim if the compound identity and stereochemistry remain within Formula IA.

4. Is claim 2 broader or narrower than claim 1?
   Claim 2 is narrower because it locks to one specific compound: 9-(R)-(2-phosphonomethoxypropyl)adenine.

5. Is HIV or HBV antiviral effect required to be demonstrated in clinical endpoints for infringement?
   The claim requires achieving an antiviral effect “in a mammal,” which in practice is satisfied by therapeutic dosing and antiviral activity evidenced in labeling or outcomes; exact evidentiary standards depend on litigation posture and proof burdens.

---

References

1. United States Patent 6,057,305 (claims as provided in the prompt).

Drugs Protected by US Patent 6,057,305

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

International Family Members for US Patent 6,057,305

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	179983
Canada	2141589
Canada	2574904
Czech Republic	290797
Czech Republic	293533